Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
NCT06068153 · ETOP IBCSG Partners Foundation · PHASE2 · withdrawn · last registry update 2024-11-20 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “In view of the recent developments in the field (the increasing number of trials with new KRAS inhibitors), the window of opportunity to answer the question raised in the AMBER trial was missed.” | Open Targets' class: another study | Registry record, ETOP IBCSG Partners Foundation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KRAS in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-15Also stopped (withdrawn): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Adagrasib + Adagrasib/Nivolumab (NCT05472623)
- 2025-05-01Results posted on the registry: Vitrac Therapeutics, LLC, VIC-1911 + sotorasib (NCT05374538)
- 2025-05-01Also stopped (terminated): Vitrac Therapeutics, LLC, VIC-1911 + sotorasib (NCT05374538)
- 2025-04-25Also stopped (terminated): Mirati Therapeutics Inc., Adagrasib + nab-Sirolimus (NCT05840510)
- 2025-03-13Phase 3 first posted: Mirati Therapeutics Inc., Adagrasib + Pembrolizumab (NCT06875310)
- 2025-01-22Results posted on the registry: Mirati Therapeutics Inc., MRTX849 + Docetaxel (NCT04685135)
- 2024-12-12Also stopped (terminated): Navire Pharma Inc., a BridgeBio company, BBP-398 + sotorasib (NCT05480865)
- 2024-07-11Phase 3 first posted: Hoffmann-La Roche, Divarasib + Sotorasib (NCT06497556)
- 2024-03-29Also stopped (withdrawn): NYU Langone Health, Sotorasib + Ladarixin (NCT05815186)
- 2024-01-23Also stopped (withdrawn): M.D. Anderson Cancer Center, Durvalumab + Adagrasib (NCT05848843)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision